Replies to post #238590 on Biotech Values

[DewDiligence]

ITRM -39%/PM on CRL:

https://www.globenewswire.com/news-release/2021/07/26/2268441/0/en/Iterum-Therapeutics-Receives-Complete-Response-Letter-from-U-S-Food-and-Drug-Administration-for-Oral-Sulopenem.html

Surprising selloff insofar as the CRL was telegraphed on 7/1/21 (#msg-164711131).